381 |
Efeito do inibidor de proteinase de origem vegetal EcTI, sobre a lesão pulmonar induzida pela elastase em camundongos C57BI6 / Effects of proteinase inhibitor from plant EcTI on elastase-induced lung alterations in miceOsmar Aparecido Theodoro Junior 02 June 2014 (has links)
Introdução: As proteinases tem um papel importante no desenvolvimento, na destruição tecidual e na produção de muco causada pela DPOC. O inibidor de proteinase de origem vegetal Enterolobium contortisiliquum Tripsin Inhibitor (EcTI) inibe tanto as proteinases da classe serina quanto da classe cisteína. Objetivos: Avaliar os efeitos do tratamento com EcTI nas alterações pulmonares induzidas pela elastase em camundongos. Métodos: Camundongos C57Bl6 receberam elastase via intratraqueal (50 uL/animal, grupo ELA) ou salina (grupo SAL). Os camundongos foram tratados com EcTI (2mg/kg) nos dias 1, 15 e 21 após a instilação de elastase (grupo ELA-EcTI) ou salina (grupo SAL-EcTI). No dia 28 do protocolo, os animais foram anestesiados, a mecânica pulmonar foi medida e o óxido nítrico exalado coletado. Posteriormente, foi realizado o lavado broncoalveolar e os pulmões foram removidos para a preparação de lâminas de histoquímica e imunohistoquímica. Por meio de morfometria analisamos o número de células positivas para neutrófilos, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS assim como a fração de volume de 8-iso-PGF2alfa, fibras colágenas e elásticas, nos septos alveolares e nas vias aéreas. Também foram avaliados o número de células positivas para macrófagos nos septos alveolares e MUC5ac nas vias aéreas. Resultados: O inibidor de proteinase EcTI reduziu as alterações de mecânica pulmonar (Ers, Htis e Raw), destruição do septo alveolar (Lm) e o número de células no lavado broncoalveolar (células totais, macrófagos, neutrófilos, linfócitos e eosinógilos) induzidos pela elastase. Em relação a resposta inflamatória, o EcTI reduziu o número de neutrófilos e de células TNFalfa positivas no septo alveolar e nas vias aéreas além de reduzir o número de macrófagos no septo alveolar. Considerando o remodelamento de matriz extracelular, o inibidor de proteinase atenuou a fração de volume de fibras colágenas e o número de células MMP-9 e MMP-12 positivas nos septos alveolares e nas vias aéreas. Além disso, nas vias aéreas ocorreu uma atenuação da fração de volume de fibras elásticas, e nos septos alveolares uma atenuação da quantidade de células que expressam TIMP-1. Em relação a resposta de estresse oxidativo, o EcTI reduziu a fração de volume de isoprostano e o número de células iNOS e eNOS positivas tanto nos septos alveolares quanto nas vias aéreas. O EcTI também reduziu o número de células MUC5ac positivas nas vias aéreas. Conclusões: O tratamento como inibidor EcTI modulou a mecânica pulmonar e reduziu as alterações inflamatórias, de remodelamento e de estresse oxidativo induzidas pela elastase intratraqueal. Embora sejam necessários mais estudos para elucidar os mecanismos envolvidos neste processo, o inibidor de proteinase EcTI pode ser considerado como um potencial instrumento terapêutico para o tratamento da DPOC / Background: Proteinases play a key role on emphysema development, tissue destruction and mucus production. Enterolobium contortisiliquum Tripsin Inhibitor (EcTI) is a proteinase inhibitor from plant that neutralizes serine and cysteine proteinases. Aims: To evaluated the effects of the EcTI treatment in pulmonary alterations induced by elastase in mice. Methods: C57Bl6 mice received elastase intratracheally (50 uL/animal, ELA group) or saline (SAL group). Afterwards, mice were treated with EcTI (2 mg/kg) at days 1, 15 and 21 after elastase instillation (ELA-EcTI group). Control group received saline and EcTI using the same protocol (SAL-EcTI group). At day 28, mice were anesthetized, respiratory mechanics were collected, and exhaled nitric oxide were analyzed. Afterwards, broncoalveolar lavage fluid was obtained and lungs were removed to perform histochemistry and immunohistochemistry stains. By morphometry, the number of neutrophils, TNF-alfa, MMP-9, MMP-12, TIMP-1, iNOS, eNOS positive cells as well as the volume proportion of 8-iso-PGF2alfa, collagen and elastic fibers content in alveolar septum and airways walls were performed. In airways walls, we also analyzed the number of MUC-5 positive cells and the number of macrophages. Results: The proteinase inhibitor EcTI was able to reduce the pulmonary mechanical alterations (Ers, Htis and Raw), alveolar septum disruption (Lm) and the BAL cell count (total cells, macrophages, neutrophils, lymphocytes and eosinophils) induced by elastase. Regarding the inflammatory response, EcTI also reduced the number of neutrophils and TNFalfa positive cells in both alveolar septum and airway walls, and also reduced the number of macrophages in alveolar septum. Considering the extracellular matrix remodeling, the proteinase inhibitor attenuated the volume fraction of collagen fibers, MMP-9 and MMP-12 positive cells in both alveolar septum and airway walls. Besides, in airway there were attenuation in the volume fraction of elastic fibers, and in the alveolar septa a decrease of the amount of the cells expressing TIMP-1. Regarding the oxidative stress response, EcTI reduced the volume fraction of isoprostane and the number of iNOS and eNOS positive cells in both airways walls and alveolar septa, Finally, EcTI reduced the number of MUC5ac positive cells in airway walls. Conclusions: The treatment with EcTI modulated lung mechanics and reduced inflammatory, remodeling and oxidative stress alterations induced by elastase. Although more studies need to be performed to elucidate the mechanisms involved in this process, we may considerate EcTI as a potential therapeutic tool for COPD management
|
382 |
Chemistry Of Tetrathiomolybdate : Application In Organic SynthesisBaig, Nasir Baig Rashid 07 1900 (has links)
The thesis entitled “Chemistry of Tetrathiomolybdate: Applications in Organic Synthesis” is divided in to six chapters
Chapter 1: Synthesis of -amino disulfides, cystines and their direct incorporation into peptides mediated by tetrathiomolybdate
In this chapter, we report a simple method for direct access to β-amino disulfides by regioselective ring opening of sulfamidates with benzyltriethylammonium tetrathiomolybdate [BnEt3N]2MoS4. The versatility of this reaction has been shown by preparing a number of β-amino disulfides having different N-protecting groups and the stability of these protecting groups under the reaction conditions has been evaluated.
This methodology is also extended to the synthesis and direct incorporation cystine and 3, 3′-dimethyl cystine derivatives into peptides.
Chapter 2: Unusual reactivity of tetrathiomolybdate: A new entry to the synthesis of b-aminothiols
In this chapter, we disclose a simple and highly efficient method for the synthesis of β and γ-amino thiols via regioselective ring opening of sulfamidates with tetrathiomolybdate 1. The scope and generality of this methodology has been exemplified by synthesizing a carbohydrate derived β-aminothiol.
This methodology has also been extended to the synthesis of isocysteine derivatives in optically pure form.
Chapter 3: Part 1: Synthesis of β-aminodiselenides via sequential one-pot, multistep reactions mediated by tetrathiomolybdate
In this chapter, we have demonstrated that a variety of N-alkyl-β-aminodiselenides can be synthesized in high yield from appropriate sulfamidates under mild reaction conditions using potassium selenocyanate and tetrathiomolybdate [BnEt3N]2MoS4 via a sequential one-pot multistep process. The compatibility of different protecting groups under the reaction conditions has been discussed.
Chapter: 3 Part 2: Synthesis of unnatural seleno amino acids and their direct incorporation into peptides
In this chapter, we have demonstrated the first and general method for the synthesis of selenocystine, 3, 3'-dialkylselenocystine, isoselenocystine and their direct incorporation into peptides using a one-pot multistep reaction strategy mediated by tetrathiomolybdate.
Chapter 4: Synthesis and functionalization of cysteine, selenocysteine and their derivatives via the formation of unsymmetrical disulfide and sulfur-selenium bond.
In this chapter, we present a novel one-pot multi component strategy for the synthesis and functionalization of cysteine, selenocysteine and their derivatives via unsymmetrical disulfides and sulfur-selenium bond formation.
Chapter 5: Part 1: A novel method for the synthesis of thioacetates employing benzyltriethylammonium tetrathiomolybdate and acetic anhydride
In this chapter, we report a simple and efficient methodology for the synthesis of thioacetates using benzyltriethylammonium tetrathiomolybdate [BnEt3N]2MoS4 and acetic anhydride as the key reagents, starting from alkyl halides in a multi step, tandem reaction process.
The application of this methodology for the synthesis of orthogonally protected cysteine derivatives and anomeric β-thioglycosides has also been demonstrated.
Chapter 5: Part 2: One-pot synthesis of β-aminothioacetates using benzyltriethyl-ammonium tetrathiomolybdate and acetic anhydride.
In this chapter, we have demonstrated a simple and efficient method for the synthesis of β-amino thioacetates and pseudo thioinositol derivatives, via ring opening of aziridines and aziridino epoxides using tetrathiomolybdate 1 and acetic anhydride as key reagents.
Chapter 6: Simple and efficient synthesis of allo and threo-3, 3'-dimethylcystine derivatives in optically pure form
In this chapter, we have presented a simple and efficient methodology for the synthesis of allo-3,3'-dimethylcystine and threo-3,3'-dimethylcystine derivatives in optically pure form using L-threonine as the chiral pool and benzyltriethylammonium tetrathiomolybdate 1 as the key reagent.
(For structural formula pl see the pdf file)
|
383 |
Sensory neuronal protection & improving regeneration after peripheral nerve injuryMcKay Hart, Andrew January 2003 (has links)
Peripheral nerve trauma is a common cause of considerable functional morbidity, and healthcare expenditure. Particularly in the ~15% of injuries unsuitable for primary repair, standard clinical management results in inadequate sensory restitution in the majority of cases, despite the rigorous application of complex microsurgical techniques. This can largely be explained by the failure of surgical management to adequately address the neurobiological hurdles to optimal regeneration. Most significant of these is the extensive sensory neuronal death that follows injury, and which is accompanied by a reduction in the regenerative potential of axotomised neurons, and in the supportive capacity of the Schwann cell population if nerve repair is delayed. The present study aimed to accurately delineate the timecourse of neuronal death, in order to identify a therapeutic window during which clinically applicable neuroprotective strategies might be adopted. It then proceeded to investigate means to increase the regenerative capacity of chronically axotomised neurons, and to augment the Schwann cells’ ability to promote that regenerative effort. Unilateral sciatic nerve transection in the rat was the model used, initially assessing neuronal death within the L4&5 dorsal root ganglia by a combination of morphology, TdT uptake nick-end labelling (TUNEL), and statistically unbiased estimation of neuronal loss using the stereological optical disector technique. Having identified 2 weeks, and 2 months post-axotomy as the most biologically relevant timepoints to study, the effect upon neuronal death of systemic treatment with acetyl-L-carnitine (ALCAR 10, or 50mg/kg/day) or N-acetyl-cysteine (NAC 30, or 150mg/kg/day) was determined. A model of secondary nerve repair was then adopted; either 2 or 4 months after unilateral sciatic nerve division, 1cm gap repairs were performed using either reversed isografts, or poly-3-hydroxybutyrate (PHB) conduits containing an alginate-fibronectin hydrogel. Six weeks later nerve regeneration and the Schwann cell population were quantified by digital image analysis of frozen section immunohistochemistry. Sensory neuronal death begins within 24 hours of injury, but takes 1 week to translate into significant neuronal loss. The rate of neuronal death peaks 2 weeks after injury, and neuronal loss is essentially complete by 2 months post-axotomy. Nerve repair is incompletely neuroprotective, but the earlier it is performed the greater the benefit. Two clinically safe pharmaceutical agents, ALCAR & NAC, were found to virtually eliminate sensory neuronal death after peripheral nerve transection. ALCAR also enhanced nerve regeneration independently of its neuroprotective role. Plain PHB conduits were found to be technically simple to use, and supported some regeneration, but were not adequate in themselves. Leukaemia inhibitory factor enhanced nerve regeneration, though cultured autologous Schwann cells (SC’s) were somewhat more effective. Both were relatively more efficacious after a 4 month delay in nerve repair. The most profuse regeneration was found with recombinant glial growth factor (rhGGF-2) in repairs performed 2 months after axotomy, with results that were arguably better than were obtained with nerve grafts. A similar conclusion can be drawn from the result found using both rhGGF-2 and SC’s in PHB conduits 4 months after axotomy. In summary, these findings reinforce the significance of sensory neuronal death in peripheral nerve trauma, and the possibility of its` limitation by early nerve repair. Two agents for the adjuvant therapy of such injuries were identified, that can virtually eliminate neuronal death, and enhance regeneration. Elements in the creation of a bioartificial nerve conduit to replace, or surpass autologous nerve graft for secondary nerve repair are presented.
|
384 |
Studies of Autoantibodies in Systemic and Organ-Specific Autoimmune DiseaseSköldberg, Filip January 2003 (has links)
Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease, whereas autoimmune polyendocrine syndrome type 1 (APS1) is a rare autosomal disorder characterized by combinations of organ-specific autoimmune manifestations including hypoparathyroidism and intestinal dysfunction, and may serve as a model for organ-specific autoimmunity. Autoantibodies directed against proteins expressed in the affected tissues are found in both diseases. From a chondrocyte cDNA expression library, we identified the protein AHNAK as an autoantigen in SLE. Anti-AHNAK antibodies were found in 29.5% (18/61) of patients with SLE, 4.6% (5/109) of patients with rheumatoid arthritis, and 1.2% (2/172) of blood donors. Using a candidate approach, we analyzed the prevalence in APS1 and other organ-specific autoimmune diseases, of autoantibodies against the pyridoxal phosphate-dependent enzymes histidine decarboxylase (HDC) and cysteine sulfinic acid decarboxylase (CSAD), which are structurally closely related to known autoantigens. Anti-HDC and anti-CSAD reactivity was detected exclusively in APS1 patient sera. Anti-HDC antibodies were detected in 37.1% (36/97) of the APS1 sera, did not cross-react with aromatic L-amino acid decarboxylase, and were associated with intestinal dysfunction and loss of histamine-producing gastric enterochromaffin-like cells. In contrast, anti-CSAD reactivity was detected in 3.6% (3/83) of APS1 sera and cross-reacted with recombinant glutamic acid decarboxylase. From a parathyroid cDNA expression library, novel spliced transcripts of the CLLD4 gene on human chromosome 13q14, encoding 26 and 31 kDa isoforms recognized by autoantibodies in 3.4% (3/87) of APS1 patients, were identified and found to be preferentially expressed in lung and ovary. Both isoforms contain an N-terminal BTB/POZ domain, similarly to the TNF-alpha-regulated protein B12, localize both to the cytoplasm and nucleus in transfected COS cells, and form oligomers in vitro. The CLLD4 gene is located in a region frequently deleted in several forms of cancer, including lung and ovarian tumors. In conclusion, we have identified and partially characterized AHNAK and HDC as two common targets of autoantibodies in SLE and APS1, respectively. We have also identified CSAD and CLLD4 as two minor autoantigens in APS1, one of which is a novel protein with unknown function.
|
385 |
Proteome-wide Identification of New Molecular Targets Affected by Methotrexate in Acute Promyelocytic Leukaemia Cell Line / Proteome-wide Identification of New Molecular Targets Affected by Methotrexate in Acute Promyelocytic Leukaemia Cell LineAgarwal, Nitin Kumar 02 May 2007 (has links)
No description available.
|
386 |
Regulation of Myoplasmic Ca2+ During Fatigue in KATP Channel Deficient FDB Muscle FibresSelvin, David 23 September 2013 (has links)
It is known that muscles that lack KATP channel activity generate much greater unstimulated [Ca2+]i and force than normal muscles during fatigue. The increase in unstimulated force in KATP channel deficient muscles is abolished by a partial inhibition of L-type Ca2+ channels, suggesting that it is due to a Ca2+ influx through L-type Ca2+ channels and a subsequent increased myoplasmic Ca2+. However, there is also evidence that the increase in resting force is abolished by NAC, a ROS scavenger. The objective of this study was to reconcile these observations by studying the hypothesis that “the increase in resting [Ca2+]i during fatigue in KATP channel deficient muscles starts with an excess Ca2+ influx through L-type Ca2+ channels, followed by an excess ROS production that causes a further increase in resting [Ca2+]i”. To test the hypothesis, single FDB fibres were fatigued with one tetanic contraction/sec for 180 sec. KATP channel deficient fibres were obtained i) by exposing wild type muscle fibers to glibenclamide, a KATP channel blocker and ii) by using fibres from Kir6.2-/- mice, which are null mice for the Kir6.2 gene that encodes for the protein forming the channel pore. Verapamil, a L-type Ca2+ channel blocker, applied at 1 μM, significantly reduced resting [Ca2+]i during fatigue in glibenclamide-exposed wild type fibres. NAC (1 mM) also reduced resting [Ca2+]i in glibenclamide-exposed muscles. The results suggest that the increase in resting [Ca2+]i during fatigue in KATP channel deficient FDB fibres is due to an influx through L-type Ca2+ channels, and an excess ROS production.
|
387 |
Identification de protéines impliquées dans le guidage du tube pollinique par les ovules de Solanum chacoenseViallet, Claire 08 1900 (has links)
No description available.
|
388 |
Detekce a kvantifikace inhibitorů proteáz v klíštěti \kur{Ixodes ricinus} pomocí monoklonálních protilátekVANÍČKOVÁ, Martina January 2017 (has links)
Inhibitors of proteases in tick saliva play an important role during tick feeding. Tick saliva contains a wide range of bioactive components which are able to modulate host imunity. Therefore, ticks are able to feed for a long time and transfer tick-borne diseases pathogens. The risk of transfer can be significantly reduced by deactivation of theese protease inhibitors. In this study I made monoclonal antibodies for detection and quantification of two serine protease inhibitors in tick saliva and other tick-body parts.
|
389 |
Estudos in vitro e in vivo da atividade leishmanicida de novos derivados sintéticos / Studies in vitro and in vivo of the leishmanicidal activity of noval sintetic derivativesQueiroz, Aline Cavalcanti de 26 February 2015 (has links)
The arsenal of drugs available for treating Leishmania infections is limited and presents high toxicity. Therefore, new, effective, and less toxic leishmaniasis treatments are still needed. In this work, two series of derivatives, containing a semicarbazone or hydrazide-N- acylhydrazone scaffolds was designed and synthetized as protease inhibitors. From these series, derivatives LASSBio 1483, LASSBio 1705, LASSBio 1707 and LASSBio 1736 highlighted, showing in vitro and in vivo leishmanicidal activities. Thus, these derivatives presented a potent leishmanicidal activity against amastigotes of L. major (IC50 of 1.5 µΜ to LASSBio 1483, 8.5 µΜ to LASSBio 1705 and 1.,9 µΜ to LASSBio 1707) , L. amazonensis (IC50 of 3.5 µΜ to LASSBio 1483 and 84.0 µΜ to LASSBio 1736), L. braziliensis (IC50 of 31.7 µΜ to LASSBio 1483, 8.0 µΜ to LASSBio 1705 and 5.3 µΜ to LASSBio 1736) and L. chagasi (IC50 of 53.3 µΜ to LASSBio 1707 and 57,6 µΜ to LASSBio 1736). Also, the leishmanicidal activity of derivatives LASSBio-1483, LASSBio 1705, LASSBio 1707 and LASSBio 1736 were mediated via induction of apoptosis as evidenced by externalization of phospholipids, despolarization of mitochondrial membrane and elevation of activation of caspases. The ultrastructural morphological effects against the parasite of LASSBio 1483 and LASSBio 1736 against L. chagasi promastigotes were also verified. The treatment of L. amazonensis -infected BALB/c mice with derivatives LASSBio 1483 (effect of 30.5% and 33.3% in infected ear, by p.o and i.p., respectively), LASSBio 1705 1483 (effect of 58.5% in infected ear and 61.1% in lymph node, i.p.), LASSBio 1707 (effect of 56.5% in lymph node, i.p.) and LASSBio 1736 (effect of 53.6% in infected ear, i.p.)or the treatment of L. chagasi - infected hamsters with LASSBio 1707 (effect of 53.6, i.p.)and LASSBio 1736 (effect of 46.0%, i.p.) led to a significant reduction of parasite burden when compared to controls that received PBS. The treatment with these derivatives did not result in hepatic or renal toxicity in these animals models of leishmaniasis. These data make LASSBio 1483, LASSBio 1705, LASSBio 1707 and LASSBio 1736 new lead-candidates against cutaneous and visceral leishmaniasis. / Conselho Nacional de Desenvolvimento Científico e Tecnológico / O arsenal de fármacos disponíveis para o tratamento das infecções por Leishmania spp. é limitada e de elevada toxicidade. Portanto, novos tratamentos, eficazes e menos tóxicos para leishmaniose ainda são necessários. Neste trabalho, duas séries de derivados contendo as subunidades semicarbazona ou hidrazida-N-acilhidrazona foram desenhados e sintetizados como inibidores de proteases. A partir destas séries, os derivados LASSBio 1483, LASSBio 1705, LASSBio 1707 e LASSBio 1736 se destacaram, mostrando atividade leishmanicida in vitro e in vivo . Assim, esses derivados apresentaram atividade leishmanicida potente contra amastigotas de L. major (CI 50 de 1,5 µΜ para LASSBio 1483, 8,5 µΜ para LASSBio 1705 e 15,9 µΜ para LASSBio 1707) , L. amazonensis (CI 50 de 3,5 µΜ para LASSBio 1483 e 84,0 µΜ para LASSBio 1736) , L. braziliensis (CI 50 de 31,7 µΜ para LASSBio 1483, 8,0 µΜ para LASSBio 1705 e 5,3 µΜ para LASSBio 1736) e L. chagasi (CI 50 de 53,3 µΜ para LASSBio 1707 e 57,6 µΜ para LASSBio 1736). Além disso, a atividade leishmanicida dos derivados LASSBio 1483, LASSBio 1705, LASSBio1707 e LASSBio 1736 foi mediada via indução de apoptose como evidenciado pela externalização de fosfolipídeos de membrana, despolarização da membrana mitocondrial e ativação de caspases. Os efeitos morfológicos ultra-estruturais de LASSBio 1483 e LASSBio 1736 em promastigotas de L. chagasi também foram verificados. O tratamento de camundongos BALB/c infectados por L. amazonensis com os derivados LASSBio 1483 (efeito de 30,5% e 33,3% na orelha infectada, por v.o. e i.p., respectivamente), LASSBio 1705 (efeito de 58,1% na orelha infectada e de 61,1% no linfonodo, i.p.) , LASSBio 1707 (efeito de 56,5% no linfonodo, i.p.) e LASSBio 1736 (efeito de 38,8% na orelha infectada , i.p.) ou o tratamento de hamsters infectados por L. chagasi com LASSBio 1707 (efeito de 53,6%, i.p.) e LASSBio 1736 (efeito de 46,0%, i.p.), na dose de 30 µmols/kg/dia, levaram a uma redução significativa da carga parasitária quando comparados aos controles que receberam PBS. O tratamento com estes derivados não resultaram em toxicidade hepática ou renal nestes modelos animais de leishmaniose. Estes dados fazem de LASSBio-1483, LASSBio-1705, LASSBio-1707 e LASSBio-1736 novos candidatos a protótipos a fármacos contra leishmaniose cutânea e visceral
|
390 |
Synthetic phosphorylation of kinases for functional studies in vitroChooi, Kok Phin January 2014 (has links)
The activity of protein kinases is heavily dependent on the phosphorylation state of the protein. Kinase phosphorylation states have been prepared through biological or enzymatic means for biochemical evaluation, but the use of protein chemical modification as an investigative tool has not been addressed. By chemically reacting a genetically encoded cysteine, phosphocysteine was installed via dehydroalanine as a reactive intermediate. The installed phosphocysteine was intended as a surrogate to the naturally occurring phosphothreonine or phosphoserine of a phosphorylated protein kinase. Two model protein kinases were investigated on: MEK1 and p38α. The development of suitable protein variants and suitable reaction conditions on these two proteins is discussed in turn and in detail, resulting in p38α-pCys180 and MEK1-pCys222. Designed to be mimics of the naturally occurring p38α-pThr180 and MEK1-pSer222, these two chemically modified proteins were studied for their biological function. The core biological studies entailed the determination of enzymatic activity of both modified proteins, and included the necessary controls against their active counterparts. In addition, the studies on p38α-pCys180 also included a more detailed quantification of enzymatic activity, and the behaviour of this modified protein against known inhibitors of p38α was also investigated. Both modified proteins were shown to be enzymatically active and behave similarly to corresponding active species. The adaptation of mass spectrometry methods to handle the majority of project's analytical requirements, from monitoring chemical transformations to following enzyme kinetics was instrumental in making these studies feasible. The details of these technical developments are interwoven into the scientific discussion. Also included in this thesis is an introduction to the mechanism and function of protein kinases, and on the protein chemistry methods employed. The work is concluded with a projection of implications that this protein chemical modification technique has on kinase biomedical research.
|
Page generated in 0.4754 seconds